BACKGROUND: Poor medication adherence among patients with chronic diseases can result in complications and increased health care expenditures. An outpatient pharmacy clinical service (OPCS) program targeted nonadherent diabetes mellitus (DM) and/or coronary artery disease (CAD) patients with hemoglobin A1c (HbA1c) and/or low-density lipoprotein cholesterol (LDL-C) outside clinical goals. Pharmacists engaged identified patients with a face-to-face B-SMART consult, a consultation methodology to identify Barriers to medication adherence, work on Solutions to identified barriers, Motivate patients, recommend Adherence tools, reinforce the pharmacist-patient Relationship, and Triage if needed, to other services such as health education to improve outcomes.
OBJECTIVES: To (a) assess rates of medication adherence and clinical outcomes in the OPCS program compared with usual care in an integrated health care system and (b) estimate return-on-investment (ROI) from this intervention.
METHODS: This retrospective cohort study used data from the Kaiser Permanente Southern California region to identify patients who received OPCS consultations and usual care patients from March 2009 through December 2010, with 1 year of follow-up from the initial consult (index date). Four patients from usual care were matched to each patient in the OPCS program and were assigned the same index date as the matching OPCS patient. Additional selection criteria were applied after matching. All patients were required to have a medication possession ratio (MPR) of < 0.80 for their diabetes or dyslipidemia oral medications 1 year prior to the index date, indicating lower adherence to the prescribed therapy. Diabetic patients or dyslipidemic patients had to have a HbA1c or LDL-C lab result outside of clinical goals prior to the index date to be included in the study, respectively. Adherence outcomes as well as clinical outcomes were measured 12 months after the index date using chi-square tests for differences in percentages and t-tests for differences in means. The ROI was based on a cost-avoidance model that compared the cost of the OPCS program with the cost savings gained through reduced hospitalizations and emergency department (ED) visits. The diabetes and dyslipidemia cohorts were combined for the ROI analysis.
RESULTS: Demographic and clinical characteristics at baseline were similar between the OPCS group (n = 1,480) and usual care group (n = 1,477). Among patients with diabetes, a higher percentage in the OPCS group than in the usual care group were adherent with their diabetes medications (53.5% vs. 37.4%, P = 0.001). There was no significant difference in average MPR between groups. However, patients in the OPCS group had a greater increase in mean MPR (0.19 vs. 0.15, P = 0.024); were less likely to discontinue taking their diabetes medications (11.7% vs. 35 .5%, P = 0.001); and were more likely to have a timely first fill after the index date (34.8% vs. 12.9%, P = 0.001). The average number of days to the first fill after the
R E S E A R C H
• Patients with chronic conditions have suboptimal rates of medication adherence that can lead to poor health outcomes, increased health care costs, and mortality.
• Among patients with diabetes, dyslipidemia, and other chronic conditions, previous studies have reported improvements in medication adherence rates ranging from 2% to 39% after patients received counseling by a pharmacist in an outpatient setting. • Previous studies have also shown significant improvements in HbA1c ranging from 2.1% to 26% among patients with pharmacist intervention. Changes in low-density lipoprotein cholesterol (LDL-C) have been mixed.
What is already known about this subject
index date was significantly shorter for the OPCS group (79.3 vs. 156.3, P = 0.001). Regarding clinical outcomes, patients with diabetes in the OPCS group had a lower mean HbA1c (8.48 vs. 8.80, P = 0.024) and a greater reduction in HbA1c (-1.25 vs. -0.75, P = 0.001) than in the usual care group. They were also less likely to have an ED visit (1.67% vs. 4.21%, P = 0.040), but there was no significant difference in the percentage of patients with a hospital admission. Among patients with dyslipidemia, the mean MPR was significantly lower for the OPCS group than the usual care group (0.70 vs. 0.74, P = 0.003). There were no significant differences in the percentage of adherent patients or the change in mean MPR from baseline. However, the OPCS group was significantly less likely to discontinue dyslipidemia medications (21.1% vs. 35.4%, P < 0.001) and more likely to have a timely fill (28.3% vs. 15.1%, P < 0.001). The average days to first fill after the index date was 106.9 for the OPCS group, compared with 162.6 for the usual care group (P < 0.001). The OPCS group had a lower mean LDL-C (105.1 vs. 110.4, P = 0.001) and a greater reduction in LDL-C (-30.5 vs. -22.4, P = 0.001) than the usual care group. There were no significant differences in the percentage of patients with an ED visit or a hospital admission. In terms of ROI, assuming that 58% of hospitalizations and 8.5% of ED visits incurred in the usual care group were avoidable, approximately $5.79 could be saved for every dollar spent on the OPCS program.
A randomized controlled trial by Lee et al. (2006) enrolled older patients taking at least 4 chronic medications into a faceto-face outpatient pharmacy care program to improve medication adherence and evaluate its associated effects on blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C). 10 Adherence was measured using pill counts. Six months after randomization, the pharmacy care group mean adherence was 95.5%, compared with 69.1% in usual care (P < 0.001) and was associated with a significant reduction in systolic BP in the pharmacy care group versus usual care. However, there were no significant differences in LDL-C levels noted.
Among patients with diabetes, an evaluation of a pharmacybased program by Brennan et al. (2012) was designed to improve patients' adherence with their diabetes medications.
11
The program consisted of face-to-face counseling in the retail setting and phone calls from pharmacists based in mail order pharmacies. Patients' month-to-month supply of medications was used as the adherence measure. The program improved medication adherence rates by 2.1% compared with a control group. The authors estimated a return on investment (ROI) using a cost-avoidance model that compared the cost of the program and additional drugs used through improved adherence with the cost savings that could be gained through reduced health care costs such as hospitalizations. This resulted in an ROI of approximately $3 for every $1 spent.
The Medication Adherence Program (MAP) study demonstrated that a brief pharmacist phone call after a missed diabetes prescription refill resulted in a significant improvement in MPR compared with the control group, especially among patients whose baseline MPR was below 0.80 (0.81 study group vs. 0.71 control group; P = 0.02). 12 Additional studies have focused on the effects of pharmacist interventions on clinical outcomes instead of adherence. A randomized controlled trial of patients with poorly controlled type 2 diabetes found that patients in the pharmacist intervention group achieved a 2.1% reduction in hemoglobin A1c (HbA1c) compared with 0.9% in the control group (P = 0.03). 13 Finally, a study by Ip et al. (2013) found that the addition of a pharmacist to a health maintenance organization primary care team decreased the mean HbA1c from 9.5% to 6.99% in the study group compared with a decrease from 9.3% to 8.4% in the control group (P < 0.001).
14 They also found an 18.2% reduction in LDL-C in the study group compared with a 6.4% reduction in the control group (P < 0.0001).
While these studies measured the effectiveness of a pharmacy-based intervention, not all included both adherence and associated clinical outcomes such as HbA1c, LDL-C, emergency department (ED) visits, or hospitalizations. One study reported the cost-effectiveness of the intervention, and 1 study attempted to target patients at risk of nonadherence through the selection of patients taking 4 or more chronic medications. Our study sought to evaluate an outpatient pharmacy M edication adherence rates are estimated at 50%-60% among patients with chronic conditions, which results in worsening disease severity, increased health care costs, and mortality. [1] [2] [3] Patients aged 65 years or older that were newly initiated on a statin were found to be 43% adherent after 6 months of treatment. Another study of adult patients with type 2 diabetes found that about 45% were adherent with their oral diabetes medications over a 1-year follow-up period. 4, 5 A longitudinal study of a national sample of patients with diabetes over a 3-year period found that improved adherence to diabetes medications was associated with 13% lower odds of hospitalizations or emergency department visits. 6 Conversely, a reduction in adherence was associated with a 15% increased odds of the outcomes previously mentioned. Given the detrimental effects of nonadherence, effective interventions are needed to improve medication adherence so that patients can optimally benefit from prescribed therapies.
Despite its importance, adherence to medication therapy can be difficult to achieve for patients with chronic diseases. Some barriers to adherence may include polypharmacy, lack of knowledge about the medications, side effects, cost factors, personal beliefs, limited health literacy, poor communication with health professionals, and forgetfulness. 7, 8 Because of their specialized knowledge of medications and access to patients, outpatient pharmacists are well positioned to coach patients in overcoming barriers to adherence.
A recent study by Taitel et al. (2012) evaluated the impact of face-to-face counseling sessions by a community pharmacist among patients who initiated statin therapy. 9 The authors found that the intervention group had a medication possession ratio (MPR) of 61.8% 1 year after the intervention compared with 56.9% in the comparison group (P <0.01). The MPR is a common measure of adherence and is calculated as the sum of the days of medication supply divided by the number of days between the first fill and last refill plus the days supply of the last refill.
• 
■■ Methods Outpatient Pharmacy Clinical Services Program
The OPCS program involved a face-to-face pharmacist consult with patients meeting the OPCS criteria when these patients requested any prescription through the outpatient pharmacy. To meet the criteria, the patient had to be included in KPSC's Diabetes and/or CAD registry, had to be nonadherent (MPR < 0.80) on at least 1 oral medication for DM or dyslipidemia and at or above the HbA1c target of 8% or the LDL-C target of 100 milligrams per deciliter (mg/dL). KPSC's integrated health care system enabled the printing of a care management summary sheet (CMSS) for every patient who met the OPCS cohort criteria along with the patient prescription label. The CMSS provided a summary of the MPR and days supply remaining (DSR) on oral DM and dyslipidemia medications, as well as the most recent HbA1c and LDL-C results for each OPCS-eligible patient. Pharmacists used the summary information presented on the CMSS and engaged identified patients during prescription pickup with a face-to-face B-SMART consult. The B-SMART (Barriers, Solutions, Motivation, Adherence tools, Relationships, and Triage) methodology is a multifaceted approach used by the OPCS pharmacists to help patients more effectively use their medications (Table 1) . [15] [16] [17] Pharmacists identified patient-specific barriers to medication nonadherence, determined patient-specific workable solutions to identified barriers; motivated; recommended adherence tools; reinforced the pharmacist-patient relationship; and triaged the patient, if needed, to improve medication adherence and outcomes.
What distinguishes the KP OPCS outpatient pharmacy model is the spontaneous identification of nonadherent patients at the time the patient arrives at the pharmacy. Using the clinical information, particularly the dynamic, real-time MPR and lab values, OPCS pharmacists can actively engage patients to improve their medication adherence and likelihood of achieving clinical goals.
Prior to providing OPCS consults, pharmacists participated in 5.5 hours of online and face-to-face training. The training included clinical management reviews and competency exams on DM and dyslipidemia, training on the B-SMART consultation methodology that incorporates motivational interviewing, and workflow training to integrate the OPCS consults within the outpatient workflow. This OPCS training is available to all Kaiser Permanente outpatient pharmacists.
Study Setting
The setting for this study was the KPSC region, an integrated health care system that provides care to approximately 3.6 million members. We used a retrospective database analysis that compared patients who received OPCS consultations with similar patients from KPSC who did not receive an OPCS consultation (usual care). A list of medical record numbers for consulted patients identified the OPCS group, which was further categorized into 2 groups: (1) patients with a diabetes-related consult and (2) patients with a dyslipidemia-related consult. The index date was defined as the first consultation from March 1, 2009, through December 31, 2010. The usual care group was identified using prescription fill history. Patients were required to have at least 1 prescription for a diabetes-or dyslipidemiarelated oral medication during the same time period of March 1, 2009, through December 31, 2010. Patients on active insulin prescriptions were not included in the OPCS cohort because patients were selected for OPCS consults based on their history of oral diabetes medication usage only. We then matched every OPCS patient to 4 patients in the usual care group by age, gender, and disease state (diabetes or dyslipidemia). The usual care group was assigned the same index date as the matching patient in the OPCS group. Patients were followed for 1 year after the index date.
After matching, further inclusion and exclusion criteria were applied based on the index date. To be included in the study, patients had to be at least aged 18 years and enrolled with a pharmacy benefit for at least 1 year before and 1 year after the index date. As in the criteria for the OPCS program, patients in the study had to be listed in the KPSC Diabetes Registry or the KPSC Coronary Artery Disease Registry. These registries identify KPSC patients with DM or CAD through a combination of disease-specific diagnosis codes and medications. Patients were excluded if they resided in a skilled nursing facility for more than 10 days or had received hospice care. OPCS patients that declined the consults were excluded from the study (Figure 1) .
OPCS consultations occured when a patient was identified as nonadherent and uncontrolled, that is, at or above the HbA1c target of 8% or the LDL-C target of 100 mg/dL. Therefore, we only included those patients with an MPR < 0.80 for their 
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diabetes or dyslipidemia medications 1 year prior to the index date. OPCS clinical goals were chosen to align with the Kaiser Permanente dyslipidemia and diabetes clinical guidelines. The MPR was defined as the sum of the days supply divided by the difference of the time between the first prescription date and the date of the last prescription plus its days supply. We chose the MPR for its ease of calculation and its common usage in the literature, which would allow comparison with other studies. Among patients with diabetes, we included those whose most recent HbA1c lab result was ≥ 8%. For the dyslipidemia groups, those with a recent LDL-C lab result ≥ 100 mg/dL were included in the study. We used the lab value closest to the index date ( Figure 1 ).
We compared rates of adherence to diabetes medications and dyslipidemia medications separately between the OPCS and usual care groups 1 year after the index date. Diabetes medications included chlorpropamide, glipizide, glyburide, metformin, and pioglitazone. Dyslipidemia medications included atorvastatin, cholestyramine, colesevelam, colestipol, ezetimibe, fenofibrate, fluvastatin, gemfibrozil, lovastatin, niacin, pravastatin, rosuvastatin, and simvastatin. Adherence was defined as having an MPR ≥ 0.80. We compared average MPR and change in MPR from baseline between the 2 groups. The average time from the last prescription fill on or before the index date to the first prescription fill after the index date was analyzed, and the percentage of patients with a timely fill was compared. If the first prescription after the index date was filled within 30 days after the end of the days supply of the last prescription, then it was considered a timely fill. The percentage of patients that discontinued their diabetes or dyslipidemia medications was also compared. When a drug is not refilled within 30 days, it is commonly considered discontinued; therefore, we used 30 days to determine timely fill as well as discontinuation. If there was no refill after the index date, it was considered discontinued. If a gap of 30 days or more occurred during the study period, then it was also considered discontinued. Using the B-SMART methodology, OPCS pharmacists documented patient-reported barriers to taking the medications as prescribed. We described the top adherence barriers reported among OPCS consulted patients. 
Clinical outcomes included rates of disease-related nonelective inpatient admissions and ED visits during the 1 year after the index date. These were identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) principal diagnosis codes (Table 2 ). These codes have been used in a previous study on the impact of medication adherence on hospitalization risk in a population with diabetes and hypercholesterolemia. 2 Additional clinical outcomes included laboratory test results for HbA1c (for patients with diabetes) and LDL-C (for patients with dyslipidemia). HbA1c laboratory tests were identified using Current Procedural Terminology, Fourth Edition (CPT-4) codes or a description from the laboratory database of "Hemoglobin A1c." LDL-C tests were identified using CPT-4 codes 80061 and 83721 and included both direct and calculated procedures.
The ROI was based on a cost-avoidance model that compared the cost of the OPCS program with the cost savings gained through reduced hospitalizations and ED visits. The diabetes and dyslipidemia cohorts were combined for the ROI analysis. OPCS pharmacists spend approximately 6.9 minutes per consult (self-reported) on this service at an estimated payroll cost for California pharmacists of $87.40 per hour (salary plus benefits). 18 Additional drug costs for improved adherence to diabetes and dyslipidemia medications were based on the average difference in drug cost 1 year after the index date between the OPCS and usual care groups. Total cost avoidance and total expense of the service, including additional drug costs and pharmacist training time invested in the program, were used to estimate an ROI for the OPCS program across the entire KPSC region. Approximately 40,000 patients were estimated to be eligible for OPCS consultations during the study period.
Comparisons between the OPCS program and usual care were made using Pearson chi-square tests for differences in percentages and t-tests for differences in means. Baseline characteristics such as age, gender, average MPR, and HbA1c and LDL-C results were compared between the OPCS and usual care groups. To ensure that patients were similar at baseline, we compared the average Diagnostic Cost Groups (DxCG) score, which is a measure of comorbidity and includes patient encounter-based indicators for a variety of chronic conditions, including CAD, heart failure, diabetes, and hypertension. 19 Finally, we compared the average number of total prescriptions 1 year prior to the index date. A two-tailed P value of 0.05 was used to determine statistical significance. Using the primary outcome of adherence (percentage of patients with an MPR ≥ 0.80), we estimated that we would need about 362 patients in each group (OPCS and usual care) to detect a 10% difference in adherence at 80% power and an alpha level of 0.05. All analyses were conducted using SAS 9.2 (SAS Institute Inc., Cary, NC). The Institutional Review Board of KPSC approved this study.
■■ Results
A total of 787 patients with diabetes and 2,170 patients with dyslipidemia met the study criteria (Figure 1 ). For the diabetes cohort, there were 359 patients (45.6%) in the OPCS group and 428 (54.4%) in the usual care group. For the dyslipidemia cohort, there were 1,121 patients (51.7%) in the OPCS group and 1,049 (48.3%) in the usual care group. Demographic characteristics were similar between the OPCS and usual care groups, with the exception of age (Table 3) . Patients in the OPCS group were slightly older than those in the usual care group. There were no significant differences in clinical characteristics at baseline between the OPCS and usual care groups ( Table 3) . The average MPR, HbA1c, and LDL-C in the 12-month period before the index date were similar between the 2 groups, as were the DxCG comorbidity scores and the average number of total prescriptions.
Adherence
Among patients with diabetes, 53.5% of the OPCS group were adherent to their diabetes medications 1 year after the index date, compared with 37.4% in the usual care group (P = 0.001; Table 4 ). There was no significant difference in mean MPR between the 2 groups. However, patients in the OPCS group had a significant increase in MPR from baseline compared with the usual care group (0.19 vs. 0.15, P = 0.024). Patients in the OPCS group were significantly less likely to discontinue their diabetes medications (11.7% vs. 35.5%, P < 0.001) and more likely to have a timely fill post-index date (34.8% vs. 12.9%, P < 0.001). The average days to first prescription fill after the index date was 79.3 for the OPCS group compared with 156.3 for the usual care group (P < 0.001). 
Diagnosis

ICD-9-CM Code
Associated ICD-9-CM Codes for Disease-Related Inpatient Admissions and Emergency Department Visits
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Clinical Outcomes
Among patients with diabetes, the mean HbA1c for the OPCS group was significantly lower than the usual care group (8.48 vs. 8.80, P = 0.024), and the changes in HbA1c from baseline were also significantly reduced (-1.25 vs. -0.75, P = 0.001; Table  5 ). They were also less likely to have an ED visit (1.67% vs. 4.21%, P = 0.040), but there was no significant difference in the percentage of patients with a hospital admission. For patients with dyslipidemia, the mean LDL-C for the OPCS group was significantly lower than the usual care group (105.10 vs. 110.40, P = 0.001), and the change in LDL-C from baseline was also significantly reduced (-30.51 vs. -22.44, P = 0.001). There were no significant differences in the percentage of patients with dyslipidemia with a hospitalization or ED visit.
Return on Investment
The combined diabetes and dyslipidemia cohorts yielded a total of 24 out of 1,412 (1.70%) hospitalizations in the OPCS group and 38 out of 1,419 (2.68%) in the usual care group, which was a 58% difference between the 2 groups. The Among patients with dyslipidemia, the mean MPR was significantly lower for the OPCS group than the usual care group (0.70 vs. 0.74, P = 0.003). There were no significant differences in the percentage of adherent patients or the change in mean MPR from baseline. Patients in the OPCS group were significantly less likely to discontinue their dyslipidemia medications (21.1% vs. 35.4%, P < 0.001) and more likely to have a timely fill (28.3% vs. 15.2%, P < 0.001). The average days to first fill after the index date was 106.9 for the OPCS group compared with 162.6 for the usual care group (P < 0.001).
Using the B-SMART methodology, OPCS pharmacists documented patient-reported barriers to taking the medications as prescribed. The top 4 adherence barriers reported among OPCS patients included forgetfulness (47%), denial of condition (19%), lack of knowledge (18%), and side effects (12%), as verbally described to the pharmacist at the time of the consultation. There were 109 pharmacists that participated in OPCS consultations during the study period. 
TABLE 4
Adherence Outcomes for Patients with an OPCS Consultation Versus Usual Care
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■■ Discussion
We found that the OPCS program was associated with improved adherence and clinical outcomes compared with usual care. The trends were similar to those reported in other studies. The study by Taitel et al. assessed the impact of faceto-face consultations among new start statin users. 9 One year after the consultation, the MPR of the intervention group was 62% and the control group was 57%, an absolute difference of 5% (P < 0.01). The absolute difference in the MPR of 4% among patients using statins in our study favored the usual care group. This finding is difficult to explain, but it could be due to the older age of the OPCS group (increased forgetfulness and polypharmacy) or perhaps there were important confounding factors that were not controlled for in the study. Alternatively, more intensive interventions may be required to affect consistent adherence with statins. Taitel et al. found a significant difference in the percentage of adherent patients (defined as MPR ≥ 80%): 41% of patients in the intervention group and 34% in the control group were adherent 1 year after the consultation. We did not find a significant difference in this measure among patients using statins in our study. The difference may be one of patient selection: Patients in the Taitel et al. study were new starts, whereas in our study, the patients may have been taking statins for years and had a history of nonadherence. We did find that a timely first fill was significantly improved after an OPCS consultation, but consistent adherence to statin therapy may be a challenge.
In the study by Lee et al., patients were included if they were taking 4 or more chronic medications, a population likely to be at increased risk for nonadherence. 10 The mean baseline adherence to statin therapy was 61%, similar to the suboptimal baseline adherence for patients taking statins in our study (55%). Patients in the intervention group in the Lee et al. study had improved adherence, but this did not result in a significant difference in LDL-C levels or reductions between the intervention and control groups. We found the opposite effect: no difference in the percentage of adherent patients but clinically small yet statistically significant improvements in LDL-C levels and reductions among the OPCS group versus the usual care group. One plausible explanation could be that the interventions had a different focus. While both interventions included face-to-face counseling by the pharmacist, patients in the Lee et al. study received personalized combinations of morning, noon, evening, or bedtime blister packs according to their regimens, which resulted in a consistently high adherence rate of 96% compared with 69% in the control group (P < 0.001).
In our study, 1 component of the B-SMART methodology is triage, and patients are often referred to health education classes and other health care resources. These resources emphasize the importance of diet and lifestyle changes to improve cholesterol levels, which may have affected the average length of stay for the OPCS group was 4.7 days and for the usual care group was 5.8 days. Extrapolating the data for the usual care group to the entire OPCS-eligible population of 40,000 within KPSC would yield 622 avoidable hospitalizations (1,072 hospitalizations × 0.58). The estimated cost avoidance for hospitalizations was $11,367,548. There were 78/1,412 (5.52%) ED visits in the OPCS group and 85/1,419 (5.99%) in the usual care group, which was an 8.5% difference between the 2 groups. The estimated cost avoidance for ED visits was $272,748. Therefore, the total cost savings across the health plan that could be incurred through reduced hospitalizations and ED visits was $11,640,296.
The cost of additional diabetes and dyslipidemia medications resulting from improved adherence was $28.36 per patient, for a total of $1,134,400. The cost of OPCS pharmacist training to provide the OPCS interventions was $52,396 (109 pharmacists × 5.5 training hours × $87.40 [salary + benefits]). The cost of the OPCS program was $526,672 (6,026 hours × $87.40 [salary + benefits]). Therefore, the total cost of the OPCS program across the health plan would be $1,713,468. The ROI was calculated as the total cost savings minus the total cost of program divided by the total cost of program, or 5.79. Assuming that the 58% of hospitalizations and the 8.5% of ER visits incurred in the usual care group were avoidable as a result of the outpatient pharmacist's intervention, approximately $5.79 could be saved for every dollar spent on the OPCS program. significant changes in LDL-C among the OPCS patients, even though there was no improvement in adherence. In order to address barriers such as forgetfulness and polypharmacy during BSMART consults, pharmacists offered adherence tools and solutions specific to patient needs. These included pill boxes, associating medication taking with other routine daily activities, and medication cards.
The new guideline on the treatment of blood cholesterol by the American College of Cardiology and the American Heart Association no longer recommends specific LDL-C targets for the primary and secondary prevention of atherosclerotic cardiovascular disease.
20 During the study period, an LDL-C < 100 mg/dL was the recommended clinical target for the OPCS population. The criteria will have to evolve to align with new recommendations. Health plans that are considering implementing a similar program may consider the use of relative changes in LDL-C levels instead of firm targets as the criteria for inclusion in the program.
The MAP study was a randomized controlled trial of a medication adherence program conducted in 4 community chain pharmacies among patients with diabetes. 12 The intervention consisted of adherence support via telephone call by the pharmacist after the patient was late for a diabetes medication refill by 6 days or more. At 12 months, the MPR was significantly improved for the intervention group compared with the control group (P < 0.01). This difference was especially pronounced among patients whose MPR 1 year before randomization was less than 80% at baseline: The intervention group had an absolute increase of 0.21, whereas the control group had an increase of 0.08 (P < 0.02). We found a similar increase of 0.19 among patients in the OPCS group and 0.15 in the usual care group (P < 0.024). This suggests that targeting patients who are already nonadherent with their diabetes medications may be an effective way to promote adherence and diabetes self-management among patients enrolled in pharmacist-managed programs.
One of the interventions in the study by Brennan et al. also took a modified targeting approach through the identification of patients with diabetes who were late in filling their diabetes medications. 11 Pharmacists called these patients to discuss nonadherence and offered to refill mail prescriptions. The authors found that patients in the intervention group were 2.1% more adherent to medications for treatment of their diabetes, a small but statistically significant increase (P < 0.01). Because they used estimates of monthly supply of medications as their adherence measure, it is difficult to compare with our annual MPR measure. The authors were able to evaluate adherence after the intervention stopped, and they found that adherence in both the intervention and control groups rapidly became similar. This suggests that programs providing continuous interventions will be more effective in the long run. Our OPCS program was based on a continuous framework. As long as patients met the nonadherent criteria and had laboratory results outside the required values, they received a consultation. We found that in the OPCS group, approximately 28% of the patients taking diabetes medications and 25% of the patients taking statins had 2 or more consultations during the study period, which may have contributed to the lower discontinuation rates and more timely refills that we found in the OPCS group compared with the usual care group.
Brennan et al. also found a positive ROI. Using a cost avoidance model, they estimated that the ROI for their program was approximately 3:1. We believe that the cost-benefit ratio for pharmacy-based programs that address adherence and improve care will be positive and will save costs mainly through reduced hospitalizations and length of stays during those hospitalizations. Nonadherence to diabetes medications as well as statin therapy has been demonstrated to result in adverse outcomes, including myocardial infarction, excess hospitalizations, and mortality. 3, 21 Medication adherence that results in just a 1% reduction in HbA1c can lead to a 37% reduction in microvascular complications and a 42% risk reduction in diabetes-related death. [22] [23] [24] Although our study resulted in a 0.5% further reduction in HbA1c for the OPCS group compared with the usual care group, 61% of the OPCS group had a 1% or more reduction in HbA1c, compared with 52% of the usual care group (P = 0.008). Pharmacy-based interventions that are continuous and that target nonadherent patients are likely to demonstrate value through increased adherence, improved outcomes, and reduced health care costs.
Limitations
A major limitation of our study was that patients were not randomized to the OPCS group versus the usual care group. It is possible that the results were attributable to systematic bias introduced by selection into the usual care group versus the OPCS group or that the 2 groups differed in other ways, such as socioeconomic status or educational levels, which may have affected patients' abilities to adhere to their medications. Although the 2 groups were similar at baseline, a limited number of baseline factors were included, and we did not employ additional methods, such as propensity scoring, to further control for potential confounding. Therefore, we cannot rule out the potential for selection bias.
Second, our measure of adherence was based on pharmacy records and assumed that "a prescription filled is a prescription taken." Although this method has been shown to be reliable, it was not possible to determine if the medications were actually taken as prescribed. 25 We chose the MPR as the measure of adherence for its ease of calculation. Other measures are available, such as the continuous measure of medication gaps or the proportion of days covered. In comparison, the MPR may result in higher values; however, these measures have all been found to provide essentially the same adherence values.
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Third, the sample size may have been too small to adequately detect outcomes of low frequency, such as disease-related hospitalizations and ED visits. With the exception of fewer ED visits among patients with diabetes in the OPCS group, there were no significant differences for these outcomes between the OPCS and usual care groups. Because we extrapolated these low-frequency outcomes to the larger population, the ROI estimate must be interpreted with caution. We also did not include physician visits, laboratory, and other such costs into the ROI.
Fourth, our study evaluated the overall impact of the OPCS program and not the individual components of the B-SMART method. For instance, it was not clear if specific components such as the use of adherence tools or triaging patients to receive additional services were more important. Future studies should be designed to identify which aspects of multicomponent interventions have the greatest impact on improved adherence.
Fifth, the study was based on patients taking oral diabetes medications only; therefore, patients with diabetes may not have been comprehensively represented because the analysis did not include those taking insulin. Sixth, nonpharmacological factors that could act as confounders were not assessed. This could include physical activity, diet, and family history. Finally, patients were followed for 1 year, which may not be long enough to conclude that improving glycemic and lipid control reduces hospitalizations and ED visits.
■■ Conclusion
Managed care outpatient pharmacists can play an instrumental role in implementing case management strategies to improve quality of care for patients with DM or CAD who have poor glycemic or lipid control and suboptimal adherence. By engaging nonadherent patients to restart their DM or lipid medications during a face-to-face consult, the OPCS pharmacist was able to influence and improve medication adherence and clinical outcomes.
